Hong Kong Stock Moves: MEDBOT-B Surges Over 4% as Figma Sales Drive Revenue Growth, Overseas Expansion Accelerates

Stock News08-11

MEDBOT-B (02252) extended its gains, rising over 4% during trading. As of the latest update, the stock was up 3.51% at HK$24.18, with a turnover of HK$54.32 million. On the news front, the company recently issued a profit alert, forecasting a net profit of RMB 28 million to RMB 40 million for the first half of the year, a significant turnaround from a loss of RMB 115 million in the same period last year. This marks the company's first-ever half-year profitability. Revenue is expected to surge by approximately 200% to 230%, translating to an estimated RMB 527 million to RMB 580 million.

A key driver is the company's flagship product, the Figma surgical robot, which saw overseas revenue jump by over 450%. Overall gross margin improved by more than 15 percentage points. Haitong International attributed the company's first-half turnaround to a combination of revenue growth, gross margin improvements, and optimized cost controls. As domestic and international installations ramp up, the company's economies of scale and operating leverage are expected to gradually materialize.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1171493347?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-11 10:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1171493347","market":"nz","top_or_hot":-1,"title":"Hong Kong Stock Moves: MEDBOT-B Surges Over 4% as Figma Sales Drive Revenue Growth, Overseas Expansion Accelerates","media":"Stock News","content":"<p><b>MEDBOT-B</b> (02252) extended its gains, rising over 4% during trading. As of the latest update, the stock was up 3.51% at HK$24.18, with a turnover of HK$54.32 million. On the news front, the company recently issued a profit alert, forecasting a net profit of RMB 28 million to RMB 40 million for the first half of the year, a significant turnaround from a loss of RMB 115 million in the same period last year. This marks the company's first-ever half-year profitability. Revenue is expected to surge by approximately 200% to 230%, translating to an estimated RMB 527 million to RMB 580 million.<br><br>A key driver is the company's flagship product, the Figma surgical robot, which saw overseas revenue jump by over 450%. Overall gross margin improved by more than 15 percentage points. Haitong International attributed the company's first-half turnaround to a combination of revenue growth, gross margin improvements, and optimized cost controls. As domestic and international installations ramp up, the company's economies of scale and operating leverage are expected to gradually materialize.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stock Moves: MEDBOT-B Surges Over 4% as Figma Sales Drive Revenue Growth, Overseas Expansion Accelerates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stock Moves: MEDBOT-B Surges Over 4% as Figma Sales Drive Revenue Growth, Overseas Expansion Accelerates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-08-11 10:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>MEDBOT-B</b> (02252) extended its gains, rising over 4% during trading. As of the latest update, the stock was up 3.51% at HK$24.18, with a turnover of HK$54.32 million. On the news front, the company recently issued a profit alert, forecasting a net profit of RMB 28 million to RMB 40 million for the first half of the year, a significant turnaround from a loss of RMB 115 million in the same period last year. This marks the company's first-ever half-year profitability. Revenue is expected to surge by approximately 200% to 230%, translating to an estimated RMB 527 million to RMB 580 million.<br><br>A key driver is the company's flagship product, the Figma surgical robot, which saw overseas revenue jump by over 450%. Overall gross margin improved by more than 15 percentage points. Haitong International attributed the company's first-half turnaround to a combination of revenue growth, gross margin improvements, and optimized cost controls. As domestic and international installations ramp up, the company's economies of scale and operating leverage are expected to gradually materialize.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1100","symbol_name":"医疗保健设备","start_time":0,"source_url":"","article_id":"1171493347","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1171493347","pubTimestamp":1786415656,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"MEDBOT-B (02252) extended its gains, rising over 4% during trading. As of the latest update, the stock was up 3.51% at HK$24.18, with a turnover of HK$54.32 million. On the news front, the company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1100":"医疗保健设备","BK4588":"碎股","VXUS":"国际股票ETF-Vanguard","BK4585":"ETF&股票定投概念","KCAI":"KraneShares China Alpha Index ETF","02252":"微创机器人-B","BK1617":"AI医疗"},"translate_title":"港股走势：Figma 销售推动收入增长，海外扩张加速，MEDBOT-B 飙升超过 4%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXUS":1,"KCAI":1,"02252":1},"content_text":"MEDBOT-B (02252) extended its gains, rising over 4% during trading. As of the latest update, the stock was up 3.51% at HK$24.18, with a turnover of HK$54.32 million. On the news front, the company recently issued a profit alert, forecasting a net profit of RMB 28 million to RMB 40 million for the first half of the year, a significant turnaround from a loss of RMB 115 million in the same period last year. This marks the company's first-ever half-year profitability. Revenue is expected to surge by approximately 200% to 230%, translating to an estimated RMB 527 million to RMB 580 million.A key driver is the company's flagship product, the Figma surgical robot, which saw overseas revenue jump by over 450%. Overall gross margin improved by more than 15 percentage points. Haitong International attributed the company's first-half turnaround to a combination of revenue growth, gross margin improvements, and optimized cost controls. As domestic and international installations ramp up, the company's economies of scale and operating leverage are expected to gradually materialize.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1171493347","isCrawlerRequest":true}